Abattis Bioceuticals Corp.

Total Valuation

Abattis Bioceuticals Corp. carries a market capitalization of 14,334.00, placing it among publicly traded companies globally. Its enterprise value stands at 9.98M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Abattis Bioceuticals Corp. currently has 477.80M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 31.46, and the price-to-book ratio stands at 0.88.

Enterprise Valuation

On an enterprise value basis, Abattis Bioceuticals Corp. trades at an EV/EBITDA multiple of 5.16 and an EV/FCF ratio of 0.69. The EV/Sales ratio of 27.97 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 3.17 provides insight into valuation relative to core operating earnings.

Financial Position

Abattis Bioceuticals Corp. maintains a current ratio of 0.73, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.71, indicating elevated leverage, while an interest coverage ratio of -80.68 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

Abattis Bioceuticals Corp.'s stock has declined approximately -70% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

Income Statement

Over the trailing twelve months, Abattis Bioceuticals Corp. generated 356,876.00 in revenue and converted that into -3.04M in net income, yielding earnings per share of -0.01. EBITDA reached -3.91M, while operating income came in at -4.01M.

Balance Sheet

Abattis Bioceuticals Corp. holds 2.40M in cash and equivalents against 1.57M in total debt, resulting in a net debt position of -600,698.00. Total book value stands at 12.74M, with working capital of -1.31M providing operational flexibility.

Cash Flow

Abattis Bioceuticals Corp. produced 9.41M in operating cash flow over the past twelve months. After subtracting -5.06M in capital expenditures, free cash flow totaled 4.35M - equivalent to 0.01 per share.

Margins

Abattis Bioceuticals Corp. operates with a gross margin of 67.62, reflecting its pricing power and cost economics. The operating margin of -1,125.03 and net profit margin of -852.40 provide insight into operational efficiency.

Dividends & Yields

Scores

Abattis Bioceuticals Corp. posts an Altman Z-Score of -34.79, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.